Atezolizumab with or without Cobimetinib in Treating Participants with Colorectal Cancer with Liver Metastases before surgery

Status: Active

Description

This phase II trial studies how well atezolizumab with or without cobimetinib works in treating participants with colorectal cancer that has spread to the liver before surgery. Monoclonal antibodies, such as atezolizumab, may interfere with the ability of tumor cells to grow and spread. Cobimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving atezolizumab and cobimetinib before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.

Eligibility Criteria

Inclusion Criteria

  • Histologically and/or cytologically confirmed and radiographically measurable per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 colorectal cancer with liver metastasis. Patients may have other sites metastatic disease.
  • Liver lesion safely amenable to core needle biopsy.
  • Willing to undergo core needle biopsy of liver metastatic site.
  • Microsatellite stable disease as determined by IHC and/or PCR, or mismatch repair proficient disease as determined by IHC.
  • Plan for next therapeutic intervention to be surgical resection of metastatic disease.
  • Ability to understand and willingness to provide informed consent.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Life expectancy of > 3 months.
  • For Combination Therapy cohort only: Able to swallow pills.
  • Women of childbearing potential (WOCBP) must have a negative serum pregnancy test within 7 days prior to start of study drug. Sexually active subjects must be willing to use two medically accepted methods of contraception, one of them being a barrier method during the study and for 5 months (or 6 months for subjects on Combination Therapy cohort) after last study drug administration.
  • Absolute neutrophil count (ANC) >= 1500 ul.
  • White blood cell (WBC) counts > 2500/uL.
  • Lymphocyte count >= 300/uL.
  • Platelets >= 100,000/ul.
  • Hemoglobin (Hgb) >= 9 g/dL.
  • Total bilirubin =< 1.5 x upper limit of normal (ULN); =< 3 x ULN for patients with known Gilbert disease.
  • Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 5 x ULN.
  • Alkaline phosphatase =< 2.5 x ULN; =< 5 x ULN for patients with documented liver involvement or bone metastases.
  • Serum creatinine =< 1.5 x ULN or creatinine clearance >= 50 mL/min on the basis of the Cockcroft-Gault glomerular filtration rate estimation.
  • International normalized ratio (INR) and activated partial thromboplastin time (aPTT) =< 1.5 x ULN. * This applies only to patients who do not receive therapeutic anticoagulation; patients receiving therapeutic anticoagulation (such as low-molecular-weight heparin or warfarin) should be on a stable dose.

Exclusion Criteria

  • Prior therapy with anti-PD-1, or anti-PD-L1 therapeutic antibody or pathway targeting agents. * Patients who have received prior treatment with anti-CTLA-4 may be enrolled, provided the following requirements are met: ** Minimum of 12 weeks from the first dose of anti-CTLA-4 and > 6 weeks from the last dose. ** No history of severe immune-related adverse effects from anti-CTLA-4 (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] grade 3 and 4).
  • For Combination Therapy cohort only: Prior therapy with MEK inhibitors.
  • Anticancer therapy, including but not limited to chemotherapy, hormonal therapy, or radiotherapy, within 4 weeks prior to start of study treatment; however, the following are allowed: * Hormone-replacement therapy or oral contraceptives. * Herbal therapy > 1 week prior to start of study treatment (herbal therapy intended as anticancer therapy must be discontinued at least 1 week prior to start of study treatment). * Palliative radiotherapy for bone metastases > 2 weeks prior to start of study treatment.
  • Expected to require any other form of systemic or localized anticancer therapy while on study.
  • Adverse events from prior anticancer therapy that have not resolved to grade =< 1 except for alopecia.
  • Investigational agent within 4 weeks prior to start of study treatment (or within five half-lives of the investigational product, whichever is longer).
  • Major surgical procedure within 28 days prior to start of study treatment or anticipation of need for a major surgical procedure during the course of the study. This does not refer to the planned liver metastasectomy that is part of the study.
  • Malignancies other than the disease under study within 5 years prior to start of study treatment, with the exception of those with a negligible risk of metastasis or death and with expected curative outcome (such as adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer treated surgically with curative intent, or ductal carcinoma in situ treated surgically with curative intent) or undergoing active surveillance per standard-of-care management (e.g., chronic lymphocytic leukemia Rai stage 0, prostate cancer with Gleason score =< 6, and prostate-specific antigen [PSA] =< 10 mg/mL, etc).
  • Diagnosis of acute leukemias, accelerated/blast-phase chronic myelogenous leukemia, chronic lymphocytic leukemia, Burkitt lymphoma, plasma cell leukemia, or non-secretory myeloma.
  • Prior allogeneic bone marrow transplantation or prior solid organ transplantation.
  • Known primary central nervous system (CNS) malignancy or symptomatic CNS metastases. * Patients with asymptomatic untreated CNS disease may be enrolled, provided all of the following criteria are met: ** Evaluable or measurable disease outside the CNS. ** No metastases to brain stem, midbrain, pons, medulla, cerebellum, or within 10 mm of the optic apparatus (optic nerves and chiasm). ** No history of intracranial hemorrhage or spinal cord hemorrhage. ** No ongoing requirement for dexamethasone for CNS disease; patients on a stable dose of anticonvulsants are permitted. ** No neurosurgical resection or brain biopsy within 28 days prior to start of study treatment. * Patients with asymptomatic treated CNS metastases may be enrolled, provided all the criteria listed above are met as well as the following: ** Radiographic demonstration of improvement upon the completion of CNS-directed therapy and no evidence of interim progression between the completion of CNS-directed therapy and the screening radiographic study. ** No stereotactic radiation or whole-brain radiation within 28 days prior to start of study treatment. ** Screening CNS radiographic study >= 4 weeks from completion of radiotherapy and >= 2 weeks from discontinuation of corticosteroids.
  • Serious, non-healing wound, ulcer, or bone fracture.
  • Pregnancy, lactation, or breastfeeding.
  • History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins or Chinese hamster ovary cell products.
  • History of malabsorption or other condition that would interfere with absorption of cobimetinib.
  • Bisphosphonate therapy for symptomatic hypercalcemia. Use of bisphosphonate therapy for other reasons (e.g., bone metastasis or osteoporosis) is allowed.
  • Known clinically significant liver disease, including active viral, alcoholic, or other hepatitis; cirrhosis; fatty liver; and inherited liver disease.
  • History or risk of autoimmune disease, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener’s granulomatosis, Sjögren’s syndrome, Bell’s palsy, Guillain-Barré syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis. * Patients with a history of autoimmune hypothyroidism on a stable dose of thyroid replacement hormone, controlled type 1 diabetes mellitus on a stable insulin regimen are eligible. * Patients with eczema, psoriasis, lichen simplex chronicus of vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would be excluded) are permitted provided that they meet the following conditions: ** Patients with psoriasis must have a baseline ophthalmologic exam to rule out ocular manifestations. ** Rash must cover less than 10% of body surface area (BSA). ** Disease is well controlled at baseline and only requiring low potency topical steroids (e.g., hydrocortisone 2.5%, hydrocortisone butyrate 0.1%, flucinolone 0.01%, desonide 0.05%, aclometasone dipropionate 0.05%). ** No acute exacerbations of underlying condition within the last 12 months (not requiring psoralen plus ultraviolet A radiation [PUVA], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors; high potency or oral steroids).
  • History of idiopathic pulmonary fibrosis, pneumonitis (including drug induced), organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia, etc.), or evidence of active pneumonitis on screening chest computed tomography (CT) scan. (History of radiation pneumonitis in the radiation field (fibrosis) is permitted).
  • Treatment with systemic immunostimulatory agents (including but not limited to interferon [IFN]-alpha or interleukin [IL]-2) within 6 weeks or five half-lives of the drug (whichever is shorter) prior to start of study treatment.
  • Treatment with systemic immunosuppressive medications (including but not limited to prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 2 weeks prior to start of study treatment. * Patients who have received acute, low-dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea) may be enrolled. * The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowed.
  • History of human immunodeficiency virus (HIV) infection or active hepatitis B (chronic or acute) or hepatitis C infection. * Patients with past or resolved hepatitis B infection (defined as having a negative hepatitis B surface antigen [HBsAg] test and a positive anti-HBc [antibody to hepatitis B core antigen] antibody test) are eligible. * Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV ribonucleic acid (RNA).
  • Active tuberculosis.
  • Severe infections within 4 weeks prior to start of study treatment, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia.
  • Signs or symptoms of infection within 2 weeks prior to start of study treatment.
  • Received oral or IV antibiotics within 2 weeks prior to start of study treatment. * Patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible.
  • Administration of a live, attenuated vaccine within 4 weeks before start of study treatment or anticipation that such a live, attenuated vaccine will be required during the study. * Influenza vaccination should be given during influenza season only (approximately October to March). Patients must not receive live, attenuated influenza vaccine (e.g., FluMist) within 4 weeks prior to start of study treatment or at any time during the study.
  • History of or evidence of retinal pathology on ophthalmologic examination that is considered a risk factor for neurosensory retinal detachment, retinal vein occlusion (RVO), or neovascular macular degeneration. Patients should be excluded if they have the following risk factors for RVO: * History of serous retinopathy. * History of retinal vein occlusion (RVO). * Evidence of ongoing serous retinopathy or RVO at baseline.
  • History of clinically significant cardiac dysfunction, including the following: * Current unstable angina * Current symptomatic congestive heart failure of New York Heart Association (NYHA) class 2 or higher. * Uncontrolled hypertension >= grade 2 (patients with a history hypertension controlled with anti-hypertensives to =< grade 1 are eligible). * Left ventricular ejection fraction (LVEF) below institutional lower limit of normal (LLN) or below 50%, whichever is lower. * Uncontrolled arrhythmias. * Myocardial infarction, severe/unstable angina, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack within the previous 6 months.
  • Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications.
  • Inability to comply with study and follow-up procedures.

Locations & Contacts

North Carolina

Durham
Duke University Medical Center
Status: Active
Contact: Niharika Bansal Mettu
Phone: 919-668-1861
Email: niharika.mettu@duke.edu

Trial Objectives and Outline

PRIMARY OBJECTIVES:

I. To characterize changes in tumor-infiltrating CD4 and CD8 T cell immune responses in colorectal cancer liver metastases during atezolizumab +/- cobimetinib therapy using immunohistochemistry (IHC) analysis of formalin fixed paraffin embedded (FFPE) tumor samples.

SECONDARY OBJECTIVES:

I. To characterize changes in other tumor-infiltrating immune cells (e.g. NK cells, dendritic cells) in colorectal cancer liver metastases during atezolizumab +/- cobimetinib therapy using fluorescence-activated cell sorting (FACS) of FFPE tumor samples.

II. To explore the clinical activity (response rate, RR; disease free survival/progression free survival, DFS/PFS; overall survival, OS) of patients with colorectal cancer liver metastases treated with atezolizumab +/- cobimetinib neoadjuvantly prior to metastatectomy.

III. To describe the toxicity profile of atezolizumab +/- cobimetinib administered in patients with colorectal cancer liver metastases treated neoadjuvantly prior to metastatectomy.

EXPLORATORY OBJECTIVES:

I. To characterize changes in T cell immune infiltrates in the following settings using IHC of FFPE tumor samples: variability amongst metastatic tumors; variability between the primary tumor and pre-treatment metastatic lesions; variability between liver metastases post-treatment and banked untreated liver metastases; effect of treatment on normal liver tissue.

II. To characterize immune signature using reverse transcriptase polymerase chain reaction (RT-PCR).

III. To characterize changes in tumor infiltrating cells (tumor reactive T cells, T cell exhaustion, regulatory T cells [Treg], and myeloid-derived suppressor cells [MDSCs]) using FACS analysis.

IV. To characterize changes in circulating immune cells (tumor reactive T cells, T cell exhaustion, Treg, and MDSCs) using FACS analysis.

V. To characterize changes in T cell repertoire using T-cell receptor RT-PCR.

VI. To characterize changes in levels and amounts of immune cytokines in plasma using enzyme-linked immunosorbent assay (ELISA).

VII. To identify biomarkers in the gut microbiome that are predictive of response to therapy.

OUTLINE: Participants are assigned to 1 of 2 arms.

ARM I: Participants receive atezolizumab intravenously (IV) over 60 minutes on days 1 and 15.

ARM II: Participants receive atezolizumab IV on days 1 and 15 and cobimetinib orally (PO) once daily (QD) on days 1-21.

In both arms, treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity. Within 42 days after completion of course 2, participants undergo liver metastasectomy.

After completion of study treatment, participants are followed up every 3 months for 2 years, then every 6 months for 3 years.

Trial Phase & Type

Trial Phase

Phase II

Trial Type

Treatment

Lead Organization

Lead Organization
Duke University Medical Center

Principal Investigator
Niharika Mettu

Trial IDs

Primary ID Pro00085578
Secondary IDs NCI-2018-01068
Clinicaltrials.gov ID NCT03340558